The information on this website is intended for medical professionals only. YES I belong to this group of experts. NO I do not belong to this group of experts. Country: Germany Safety data sheets Package inserts Do You Have Questions? Give us a call. PRODUCTS SERVICE & TRAINING EVENTS ABOUT HOLOGIC CURRENT CONTACT Our fight against COVID-19. Learn more . POWERFUL INNOVATIONS. Better decisions. Outstanding results. ABOUT HOLOGIC HOLOGIC THE SCIENCE OF SURE HOLOGIC is a leading company in the development, manufacture and sale of high-quality diagnostic products, medical imaging systems and surgical articles with a focus on gynecology. COOKIE SETTINGS This website uses cookies to enable you to use our website more comfortably. Here you can find more information about how we use cookies and how you can change your settings. Absolutely necessary analysis External media CONFIRM SELECTION SELECT ALL imprint data protection

Die Informationen auf dieser Website sind ausschließlich für medizinische Fachkreise bestimmt. JA Ich gehöre zu diesem Fachkreis. NEIN Ich gehöre nicht zu diesem Fachkreis. Country: Germany Safety Data Sheets Package Inserts Haben Sie Fragen? Rufen Sie uns an. PRODUKTE SERVICE & FORTBILDUNG EVENTS ÜBER HOLOGIC AKTUELLES KONTAKT Home Aktuelles 2021 November 29 Hologic’s COVID-19 Tests Detect Omicron Variant AKTUELLES 29. NOVEMBER 2021 Hologic’s COVID-19 Tests Detect Omicron Variant MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations. Hologic conducted an analysis of genetic sequences from more than 175 Omicron-infected samples obtained through GISAID (Global Initiative On Sharing All Influenza Data, GISAID – Initiative) and determined that none of the new mutations occur within regions of the genome targeted by Hologic’s Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay or Panther Fusion® SARS-CoV-2 Assay. Hologic has also received data from clinical users in Europe indicating that the Aptima SARS-CoV-2 assay detected Omicron COVID-19 infections in samples from inbound air travelers. “We fully expect that SARS-CoV-2 will continue to evolve, as that is the natural path for viruses,” said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. “We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays.” COOKIE-EINSTELLUNGEN Diese Website verwendet Cookies, um Ihnen eine komfortablere Nutzung unserer Internetseite zu ermöglichen. Hier finden Sie weitere Informationen dazu, wie wir Cookies verwenden und wie Sie Ihre entsprechenden Einstellungen ändern können. Unbedingt erforderlich Analyse Externe Medien AUSWAHL BESTÄTIGEN ALLE AUSWÄHLEN Impressum Datenschutz